Journal article
Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel
Prostate cancer, Vol.2011(2011), 258689
2011
DOI: 10.1155/2011/258689
PMID: 22096653
Abstract
Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m2 i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks. Results. Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated. Conclusion. Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.
Details
- Title: Subtitle
- Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel
- Creators
- Filippo Francini - University of SienaAlessandra Pascucci - University of SienaEdoardo Francini - University of SienaGianluca Bargagli - University of SienaRaffaele Conca - University of SienaAntonella Licchetta - University of SienaGiandomenico Roviello - University of SienaIgnazio Martellucci - University of SienaGiorgio Chiriac - University of SienaSalvatora Tindara Miano - University of SienaGiuseppe Marzocca - University of SienaAntonio Manganelli - University of SienaRoberto Ponchietti - University of SienaVinno Savelli - University of SienaRoberto Petrioli - University of Siena
- Resource Type
- Journal article
- Publication Details
- Prostate cancer, Vol.2011(2011), 258689
- DOI
- 10.1155/2011/258689
- PMID
- 22096653
- NLM abbreviation
- Prostate Cancer
- ISSN
- 2090-3111
- eISSN
- 2090-312X
- Publisher
- Wiley
- Language
- English
- Date published
- 2011
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221245702771
Metrics
1 Record Views